148 related articles for article (PubMed ID: 36170148)
1. The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward.
Leung JG; de Leon J; Frye MA; Singh B; Cotes RO; McElroy SL
J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):565-580. PubMed ID: 36170148
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Assessing prescribing practices of clozapine before and after the implementation of an updated risk evaluation and mitigation strategy.
Curry B; Palmer E; Mounce C; Smith G; Shah V
Ment Health Clin; 2018 Mar; 8(2):63-67. PubMed ID: 29955547
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
Rollman JE; Heyward J; Olson L; Lurie P; Sharfstein J; Alexander GC
JAMA; 2019 Feb; 321(7):676-685. PubMed ID: 30778596
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
Heyward J; Olson L; Sharfstein JM; Stuart EA; Lurie P; Alexander GC
JAMA Intern Med; 2020 Feb; 180(2):301-309. PubMed ID: 31886822
[TBL] [Abstract][Full Text] [Related]
6. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
Slevin KA; Ashburn MA
J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
[TBL] [Abstract][Full Text] [Related]
7. Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program.
Borrelli EP; Lee EY; Caffrey AR
Ment Health Clin; 2020 May; 10(3):70-75. PubMed ID: 32420002
[TBL] [Abstract][Full Text] [Related]
8. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
American Pharmacists Association ; Bough M
J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
[TBL] [Abstract][Full Text] [Related]
9. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
Shane R
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
[TBL] [Abstract][Full Text] [Related]
10. FDA changes clozapine monitoring guidelines: Implications for worldwide practice.
Bastiampillai T; Gupta A; Allison S
Asian J Psychiatr; 2016 Jun; 21():19-20. PubMed ID: 27208449
[TBL] [Abstract][Full Text] [Related]
11. How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians.
Sarpatwari A; Lu Z; Russo M; Zakoul H; Lee SB; Toyserkani GA; Zhou EH; LaCivita C; Shaw KHH; Zendel L; Dal Pan GJ; Kesselheim AS
Clin Pharmacol Ther; 2024 Jun; 115(6):1293-1303. PubMed ID: 38375585
[TBL] [Abstract][Full Text] [Related]
12. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
Toyserkani GA; Huynh L; Morrato EH
Front Public Health; 2020; 8():43. PubMed ID: 32158741
[No Abstract] [Full Text] [Related]
13. Examination of risk evaluation and mitigation strategies and drug safety in the US.
Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
[TBL] [Abstract][Full Text] [Related]
14. The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities.
Toyserkani GA; Lee JH; Zhou EH
Pharmaceut Med; 2023 Sep; 37(5):349-353. PubMed ID: 37421560
[TBL] [Abstract][Full Text] [Related]
15. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018).
Huynh L; Toyserkani GA; Morrato EH
BMC Health Serv Res; 2021 Aug; 21(1):779. PubMed ID: 34362367
[TBL] [Abstract][Full Text] [Related]
16. Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?
Brooks MJ
Mayo Clin Proc; 2014 Dec; 89(12):1673-84. PubMed ID: 25441401
[TBL] [Abstract][Full Text] [Related]
17. Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues.
Leung JG; Ehret M; Love RC; Cotes RO
Expert Rev Clin Pharmacol; 2023 Mar; 16(3):177-179. PubMed ID: 36803289
[No Abstract] [Full Text] [Related]
18. What is the quality of drug safety information for patients: An analysis of REMS educational materials.
Chan HW; Russell AM; Smith MY
Pharmacoepidemiol Drug Saf; 2018 Sep; 27(9):969-978. PubMed ID: 30003610
[TBL] [Abstract][Full Text] [Related]
19. A safe in-home disposal system with every opioid prescription? Food and Drug Administration is considering a potential new Risk Evaluation and Mitigation Strategy that could impact pharmacists.
Stubbings J; Crawford SY; Menighan TE
J Am Pharm Assoc (2003); 2022; 62(2):413-418. PubMed ID: 34872856
[TBL] [Abstract][Full Text] [Related]
20. Understanding risk evaluation and mitigation strategies in organ transplantation.
Gabardi S
Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
